Abstract
BackgroundWith indications for immune checkpoint inhibitor (ICI) therapy steadily growing, immune related adverse events (irAEs) are increasingly common in the oncologists’ practice. In the absence of prospective irAE management trials,...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have